1. Gastfriend DR (2011). Intramuscular extended-release naltrexone: current evidence. Ann N Y Acad Sci 1216: 144–166.
2. Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, Oncken CA et al (2011). Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 89: 392–399.
3. NAS (1995). The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and the Private Sector. In: Fulco CE, Liverman CT, and Earley LE (eds). Board on Biobehavioral Health and Mental Disorders. National Academy Press: Washington, DC. pp 43–200.
4. ONDCP (2004). The Economic Costs of Drug Abuse in the United States. Executive Office of the President Office of National Drug Control Policy: Washington, DC
http://www.ncjrs.gov/ondcppubs/publications/pdf/economic_costs.pdf
.
5. Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, Kosten TR (2008). Substance abuse vaccines. Ann N Y Acad Sci 1141: 257–269.